Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1108-1115

  Cometta, A ^a,l   Calandra, T ^b   Gaya, H ^c   Zinner, S H ^d   De Bock, R ^e   Del Favero, A ^f   Bucaneve, G ^f   Crokaert, F ^g   Kern, W V ^h,l   Klastersky, J ^g   Langenaeken, J ^g   Micozzi, A ⁱ   Padmos, A ^j   Paesmans, M ^g   Viscoli, C ^k   Glauser, M P ^a   Martino, P ^l   Caballero, D ^l   Engelhard, D ^l   Shapiro, M ^l   Castagnola, E ^l   Massimo, L ^l   Giacchino, R ^l   Sanz, M ^l   Giacchino, M ^l   Aoun, M ^l   Oppenheim, B ^l   D'Antonio, D ^l   Follath, F ^l   Barbabietola, G ^l   Menichetti, F ^l   Montillo, M ^l   Van Lint, M T ^l   Gibson, B ^l   Resegotti, L ^l   Kibbler, C ^l   Prentice, H ^l   Van Hoof, A ^l   Van Landuyt, H ^l   Ricci, P ^l   Rosti, G ^l   Efremidis, A ^l   Di Raimondo, F ^l   Hemmer, R ^l   Hatjiyanni, M ^l   Seitanides, B ^l   Amsallen, D ^l   Estavoyer, J M ^l   Petrikkos, G ^l   Porcellini, A ^l   Berneman, Z ^l   more..

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b PICOWER INST FOR MEDICAL RESEARCH   (United States)

^c ROYAL BROMPTON HOSPITAL   (United Kingdom)

^d BROWN UNIVERSITY   (United States)

^e MIDDELHEIM HOSPITAL   (Belgium)

^f POLICLINICO MONTELUCE   (Italy)

^g JULES BORDET INSTITUTE   (Belgium)

^h UNIVERSITY HOSPITAL ULM   (Germany)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j QUEEN S UNIVERSITY   (Canada)

^k UNIVERSITY OF GENOA   (Italy)

^l NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; MEROPENEM; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; GRANULOCYTOPENIA; HUMAN; HYPOKALEMIA; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN ALLERGY; SOLID TUMOR;

EID: 9244228971     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1108     Document Type: Article

References (39)

1. Barry, A. L., and C. Thornsberry. 1991. Susceptibility tests: diffusion test procedures, p. 1117-1125. In A Balows and W. J. Hausler (ed), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C
2. Blaser, J., C. Konig, R. Fatio, F. Follath, A. Cometta, M. Glauser, and The International Antimicrobial therapy Cooperative Group of the EORTC. 1995 Multicenter quality control study of amikacin assay for monitoring once-daily dosing regimens. Ther Drug Monit. 17:133-136.
3. Breitmann, L. E. 1991. Confidence intervals assess both clinical significance and statistical significance. Ann. Intern. Med. 14:515-517.
4. Calandra, T., and A. Cometta. 1991. Antibiotic therapy for gram-negative bacteremia. Infect. Dis. Clin N Am. 5:817-834.
5. Cometta, A., J. D. Baumgartner, D. Lew, W. Zimmerli, D. Pittet, P. Chopart, U. Schaad, C. Herter, P. Eggimann, O. Huber, B. Ricou, P. Suter, R. Auckenthaler, R. Chiolero, J. Bille, C. Scheidegger, R. Frei, and M. P. Glauser. 1994. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob. Agents Chemother. 38:1309-1313.
6. Cometta, A., S. Zinner, R. de Bock, T. Calandra, H. Gaya, J. Klastersky, J. Langenaeken, M. Paesmans, C. Viscoli, M. P. Glauser, and The Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. 1995. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Agents Chemother. 39:445-452.
7. De Jongh, C. A., J. H. Joshi, and K. A. Newman. 1986. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am. J. Med. 80(Suppl. 5C):96-100
8. De Pauw, B. E., S. C. Deresinsky, R. Feld, E. F. Lane-Allman, J. P. Donnelly, and The Intercontinental Antimicrobial Study Group. 1994. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer Ann. Intern. Med. 120:834-844.
9. Dixon, W. J., M. B. Brown, L. Engelman, and R. I. Jeinrich. 1994. BMDP statistical analysis software. University of California. Berkeley
10. Edwards, J. R., P. J. Turner, and C. Wannop. 1989. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydo-peptidase-1. Antimicrob. Agents Chemother 32:215-222.
11. Eliopoulos, G. M., and C. T. Eliopoulos. 1988. Antibiotic combinations, should they be tested? Clin. Microbiol. Rev. 1:139-156.
12. EORTC International Antimicrobial Therapy Cooperative Group. 1987. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopema. N Engl. J. Med. 317:1692-1698.
13. EORTC International Antimicrobial Therapy Cooperative Group. 1991 Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients J Infect. Dis. 163:951-958.
14. EORTC International Antimicrobial Therapy Cooperative Group. 1993. In vitro activity of piperacillin/tazobactam against 365 aerobic bacteria isolated from blood in granulocytopenic cancer patients, p. 186. In Program and abstracts of the 18th International Conference on Chemotherapy. Scandanavian Society for Antimicrobial Chemotherapy, Stockholm.
15. Francioli, P., and M. P. Glauser. 1993. Synergistic activity of ceftriaxone combined with netilmicin administered once daily for treatment of experimental streptococcal endocarditis. Antimicrob Agents Chemother. 37:207-212
16. Freedman, L. S., and S. J. White. 1976. On the use of Pocock and Simon's method for balancing treatment numbers over prognostic factors in the controlled clinical trial. Biometrics 32:691-694.
17. Freifeld, A. G., T. Walsh, D. Marshall, J. Gress, S. M. Steinberg, J. Hathorn, M. Rubin, P. Jarosinsky, V. Gill, R. C. Young, and P. A. Pizzo. 1995. Monotherapy for fever and neutropenia in cancer patients. a randomized comparison of ceftazidime versus imipenem. J. Clin. Oncol. 13:165-176.
18. Gribble, M. J., A. W. Chow, S. C. Naiman, J. A. Smith, W. R. Bowie, S. L. Sacks, L. Grossman, N. Buskard, G. H. Growe, and L. H. Plenderleith. 1983. Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother. 24:388-393.
19. Immunocompromised Host Society. 1990. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. J Infect. Dis. 161:397-401.
20. International Antimicrobial Therapy Cooperative Group of the EORTC. 1993 Efficacy and toxicity of single daily dose of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia Ann Intern. Med 119:584-593.
21. Isenberg, H. D., J. A. Washington, G. V. Doern, and D. Amsterdam. 1991. Specimen collection and handling, p 2-15. In A. Balows and W. J. Hausler, Jr., K L. Herrmann, H D. Isenberg, and H. J. Shadomy (ed.), Manual of clinical microbiology, 5th ed American Society for Microbiology, Washington, D.C.
22. Iten, A., A. Cometta, P. Eggimann, H. Siegrist, and P. Francioli. 1992 The addition of netilmicin (NET) to imipenem (IMIP) does not prevent the emergence of bacteria resistant (R) to IMIP during treatment (ttt) of severe infections, p 198. In Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington. D.C.
23. Klastersky, J., R. Cappel, and D. Daneau. 1972. Clinical significance of in vitro synergism between antibiotics in gram-negative infections. Antimicrob. Agents Chemother. 2:470-474.
24. Klastersky, J., R. Cappel, and D. Daneau. 1974. Antibacterial activity in serum and urine as a therapeutic guide in bacterial infections. J Infect. Dis. 129:187-190.
25. Klastersky, J., F. Meunier-Carpentier, and J.-M. Prevost. 1977. Significance of antimicrobial synergism for the outcome of gram-negative sepsis. Am. J. Med. Sci. 273:157-161.
26. Klastersky, J., and S. H. Zinner. 1982 Synergistic combinations of antibiotics in gram-negative bacillary infections Rev Infect. Dis. 4:294-298.
27. Leyland, M. J., K. F. Bayston, J. Cohen, R. Warren, A. C. Newland, A. J. Bint, C. Cefai, D. G. White, S. A. Murray, D. Bareford, and N. B. Deaney. 1992 A comparative study of imipenem versus piperacillin plus gentamicin in the initial management of febrile neutropenic patients with haematological malignancies. J Antimicrob. Chemother 30:843-854.
28. Liang, R., R. Yung, E. Chiu, P. Y. Chau, T. K. Chan, W. K. Lam, and D. Todd. 1990. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother. 34:1336-1341
29. Nie, N. H., C. H. Hull, J. G. Jenkins, K. Steinbrenner, D. H. Bent, and H. J. Norusis. 1988. Statistical package for the social sciences. SPSS. Inc., Chicago
30. Pizzo, P. A. 1993. Management of fever in patients with cancer and treatment-induced neutropenia. N. Engl J Med 328:1323-1332.
31. Pizzo, P. A. 1995. Empirical therapy and prevention of infection in immunocompromised host, p 2686-2696. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases Churchill Livingstone, Inc., New York.
32. Pizzo, P. A., J. W. Hathorn, J. Hiemenz, M. Browne, J. Commers, and D. Cotton. 1986. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl J. Med. 315:552-558.
33. Pocock, S. J. 1983. Monitoring trial progress. p. 142-159. J Wiley and Sons. New York.
34. Rolston, K. V. I. P. Berkey, G. P. Bodey, E. J. Anaissie, N. M. Khardori, J. H. Joshi, M. J. Keating, F. A. Holmes, F. F. Cabanillas, and L. Elting. 1992. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch. Intern Med. 152:283-291.
35. Sahm, D. F., and J. A. Washington. 1991. Antibacterial susceptibility tests. dilution methods, p. 1105-1116 In A. Balows and W J Hausler, Jr , K. L. Herrmann, H. D Isenberg, and H. Shadomy (ed), Manual of clinical microbiology, 5th ed. American Society for Microbiology, Washington, D.C.
36. Schimpff, S., W. Satterlee, V. M. Young, and A. Serpick. 1971. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia N. Engl. J. Med. 284:1061-1065.
37. The Meropenem Study Group of Leuven, London and Nijmegen. 1995. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J. Antirmicrob. Chemother 36:185-200.
38. Wade, J., C. I. Bastamante, A. Devlin, R. Finley, G. Drusano, and B. Thomson. 1987. Imipenem versus piperacillin plus amikacin, empiric therapy for febrile neutropenic patients: a double blind trial. Program and Abstract of the 27th Interscience Conference on Antimicrobial Agent and Chemotherapy (Abstract)
39. Winston, D. J., H. Winston, D. A. Bruckner, and R. E. Champlin. 1991 Beta-laetam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann. Intern. Med. 115:849-859